Abstract
Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Central Nervous System Agents in Medicinal Chemistry
Title: Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Volume: 8 Issue: 4
Author(s): Roongpetch Keowkase and Yuan Luo
Affiliation:
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Abstract: Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Export Options
About this article
Cite this article as:
Keowkase Roongpetch and Luo Yuan, Mechanism of CNS Drugs and their Combinations for Alzheimers Disease, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848166
DOI https://dx.doi.org/10.2174/187152408786848166 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Apolipoproteins and Complement Factors be Biomarkers of Alzheimer’s Disease?
Current Alzheimer Research Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease
Current Drug Targets Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial: Structural Aspects of Protein Aggregation
Protein & Peptide Letters The Pro-Apoptotic Substance Thapsigargin Selectively Stimulates Re-Growth of Brain Capillaries
Current Neurovascular Research